"versionIdentifier","uuid:ID","rationale","instanceType","id"
"2","55d6c31b-c441-4fe6-a43b-dc771236af3b","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","StudyVersion_1"
